SCHEMBL5884907

SCHEMBL5884907

CCOP(=O)(Cc1cccs1)OCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.41
HDAC1 Q13547 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HTT P42858 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
MAPT P10636 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
MEN1 O00255 1/20 0.38
CASP6 P55212 1/20 0.38
KMT2A Q03164 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
HPGD P15428 2/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6978499 0.84 RAB9A (0.43) RAB9AHDAC1SMN1; SMN2HSD17B10POLB
SCHEMBL24922409 0.80 RAB9A (0.38) RAB9AHDAC1SMN1; SMN2HSD17B10POLB
SCHEMBL12227999 0.80 DPP4 (0.57) RAB9AHDAC1SMN1; SMN2HSD17B10POLB
SCHEMBL6792599 0.79 TAAR1 (0.43) RAB9ASMN1; SMN2POLBALDH1A1TSHR
SCHEMBL12669114 0.78 HDAC1 (0.46) RAB9AHDAC1HSD17B10POLBALDH1A1
SCHEMBL4369594 0.77 TSHR (0.45) RAB9ASMN1; SMN2HSD17B10POLBTDP1
SCHEMBL10987053 0.73 RAB9A (0.48) RAB9ASMN1; SMN2POLBTDP1ALDH1A1
SCHEMBL12669112 0.73 HDAC1 (0.49) HDAC1ALDH1A1GAAMAPT
SCHEMBL10247599 0.73 HPGD (0.53) RAB9ASMN1; SMN2HSD17B10POLBALDH1A1
SCHEMBL10250866 0.73 RAB9A (0.47) RAB9AHDAC1SMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250364597-A1 ELECTROLYTE AND LITHIUM-ION BATTERIES AESC JAPAN LTD. (JP) 2025-11-27 US claimed
EP-4654312-A1 ELECTROLYTE AND LITHIUM-ION BATTERIES AESC Japan Ltd. (JP) 2025-11-26 EP claimed
US-11569530-B2 Silicon-based energy storage devices with functional thiophene compounds or derivatives of thiophene containing electrolyte additives ENEVATE CORPORATION (US) 2023-01-31 US claimed
US-20250364597-A1 ELECTROLYTE AND LITHIUM-ION BATTERIES AESC JAPAN LTD. (JP) 2025-11-27 US disclosed
US-20250364597-A1 ELECTROLYTE AND LITHIUM-ION BATTERIES AESC JAPAN LTD. (JP) 2025-11-27 US disclosed
WO-2025241164-A1 ELECTROLYTE FOR LITHIUM-ION SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY COMPRISING ELECTROLYTE 远景动力技术(鄂尔多斯市)有限公司 2025-11-27 WO disclosed
EP-4654312-A1 ELECTROLYTE AND LITHIUM-ION BATTERIES AESC Japan Ltd. (JP) 2025-11-26 EP disclosed
EP-4654312-A1 ELECTROLYTE AND LITHIUM-ION BATTERIES AESC Japan Ltd. (JP) 2025-11-26 EP disclosed
CN-115869926-B Thienyl microsphere containing phosphonate functional group and preparation and application thereof 中国科学院大连化学物理研究所 2025-01-24 CN disclosed
CN-115869926-A Thienyl microsphere containing phosphonate functional group, preparation and application thereof 中国科学院大连化学物理研究所 2023-03-31 CN disclosed
US-11569530-B2 Silicon-based energy storage devices with functional thiophene compounds or derivatives of thiophene containing electrolyte additives ENEVATE CORPORATION (US) 2023-01-31 US disclosed
WO-1997028155-A1 DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY (US) 1997-08-07 WO disclosed
EP-0778284-A2 New 7-beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors MERCK & CO. INC. (US) 1997-06-11 EP disclosed
US-5510351-A PREGNANE ENZYME INHIBITOR FOR TREATING SKIN DISORDER, BALDNESS, PROSTATIC CANCER MERCK & CO., INC. (US) 1996-04-23 US disclosed
EP-0646007-A4 1995-04-26 EP disclosed
EP-0646007-A1 NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONES AS 5-g(a)-REDUCTASE INHIBITORS. MERCK & CO INC (US) 1995-04-05 EP disclosed
EP-0572166-A1 New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors MERCK & CO. INC. (US) 1993-12-01 EP disclosed
WO-1993023050-A1 NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS MERCK & CO., INC. (US) 1993-11-25 WO disclosed
WO-1993023039-A1 SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS MERCK & CO., INC. (US) 1993-11-25 WO disclosed
WO-1993023420-A1 NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS MERCK & CO., INC. (US) 1993-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11569530-B2 Silicon-based energy storage devices with functional thiophene compounds or derivatives of thiophene containing electrolyte additives TST, SELENOI, SELE RAB9A 3400/4885HDAC1 1047/4885SMN1; SMN2 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.